Literature DB >> 29794500

Predictors of Locally Advanced Disease at Presentation and Clinical Outcomes Among Cervical Cancer Patients Admitted at a Tertiary Hospital in Botswana.

Mercy Nkuba Nassali1, Melese Tadele1, Robert Michael Nkuba2, Jamieson Modimowame3, Iwuh Enyeribe1, Edwin Katse3.   

Abstract

OBJECTIVES: The aim of this study was to determine predictors of locally advanced disease at presentation and clinical outcomes among cervical cancer patients in Botswana to inform interventional strategies.
METHODS: Retrospective review of 149 medical records of new cervical cancer patients was conducted between August 2016 and February 2017 at the Princess Marina Hospital. Data collected included sociodemographics, presenting symptoms, stage of disease, comorbidities, interventions, and clinical outcomes. STATA 12 was used for data analysis. Frequencies were used to describe patient demographics and clinical variables. Bivariate and multivariate binary logistic regression analyses were used to determine association between stage of disease at presentation and patient characteristics. P ≤ 0.05 was considered significant.
RESULTS: Mean age was 49.5 years. Nine (89.2%) in 10 patients had locally advanced cervical cancer (stage IB1-IVB). Two thirds (65.1%) were human immunodeficiency virus positive. Previous cervical cancer screening was low at 38.3%. Common symptoms were abnormal vaginal bleeding, low abdominal pain, and malodorous vaginal discharge reported among 75.8%, 66.4%, and 39.6% of cases, respectively. Overall, 32 (21.5%) were declared cured, 52 (34.9%) improved, and 11 (7.4%) opted for home-based care. Hospital deaths were 41 (27.5%). Major causes of death were renal failure (48.7%) and severe anemia (39%). Thirteen (8.7%) were lost to follow-up. Being unmarried (odds ratio [OR], 3.9), lack of cervical cancer screening (OR, 6.68), presentation with vaginal bleeding (OR, 7.69), and low abdominal pain (OR, 4.69) were associated with advanced disease at presentation.
CONCLUSIONS: Lack of cervical cancer screening, vaginal bleeding, low abdominal pain, and unmarried status were associated with advanced disease at presentation. We recommend scale-up of cervical cancer screening and its integration into routine human immunodeficiency virus care. Capacity building in gynecologic oncology and palliative care services is currently critical.

Entities:  

Mesh:

Year:  2018        PMID: 29794500     DOI: 10.1097/IGC.0000000000001284

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis.

Authors:  Tiwabwork Tekalign; Mister Teshome
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

2.  Timelines to Cervical Cancer Diagnosis and Treatment at a Tertiary Hospital in Botswana.

Authors:  Mercy-Nkuba Nassali; Tadele Melese; Jamieson Modimowame; Badani Moreri-Ntshabele
Journal:  Int J Womens Health       Date:  2021-04-23

3.  Diagnosis of advanced cervical cancer, missed opportunities?

Authors:  Jérémie Mattern; Irène Letendre; Jeanne Sibiude; Cécile Pénager; Asma Jnifen; Fatoumata Souare; Sophie Ayel; Thuy Nguyen; Laurent Mandelbrot
Journal:  BMC Womens Health       Date:  2022-03-30       Impact factor: 2.809

Review 4.  Mapping Evidence on Management of Cervical Cancer in Sub-Saharan Africa: Scoping Review.

Authors:  Petmore Zibako; Mbuzeleni Hlongwa; Nomsa Tsikai; Sarah Manyame; Themba G Ginindza
Journal:  Int J Environ Res Public Health       Date:  2022-07-28       Impact factor: 4.614

5.  Cervical cancer management in Zimbabwe (2019-2020).

Authors:  Petmore Zibako; Nomsa Tsikai; Sarah Manyame; Themba G Ginindza
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

6.  Clinical and sociodemographic factors associated with late stage cervical cancer diagnosis in Botswana.

Authors:  Anne Marie McCarthy; Surbhi Grover; Tara M Friebel-Klingner; Rebecca Luckett; Lisa Bazzett-Matabele; Tlotlo B Ralefala; Barati Monare; Mercy Nkuba Nassali; Doreen Ramogola-Masire; Memory Bvochora; Nandita Mitra; Douglas Wiebe; Timothy R Rebbeck
Journal:  BMC Womens Health       Date:  2021-07-06       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.